For Novavax, the manufacturing deal should help it clear another hurdle in its bid to break into a market dominated by giants such as Sanofi, Pfizer and GlaxoSmithKline. Emergent’s facility, designated by the U.S. government as a Center for Innovation in Advanced Development and Manufacturing, can produce hundreds of millions of doses of vaccine each year, the company said.
The agreement is a key step toward filing for Food and Drug Administration approval of the vaccine, Cantor Fitzgerald analysts Charles Duncan and Pete Stavropoulos wrote in a note to investors. That will probably occur in 2021 or earlier, they said.
